Related Experiment Video
Updated: Jun 22, 2026

Comparative Strategies for Ubiquitination Detection in Mammalian Cell Lysates Using SMAD2/SMURF2 as a Model
Published on: April 17, 2026
Therapeutic strategies within the ubiquitin proteasome system
1Department of Cell Regulation, Genentech Inc., South San Francisco, CA 94080, USA. eldridge.adam@gene.com
Abstract:
The ubiquitin-dependent proteolysis system (UPS) is the main driver of regulated protein degradation in all eukaryotic cells, and it is becoming increasingly clear that defects within this pathway drive a large number of human pathologies. Recent success in the use of proteasome inhibitors in the treatment of hematological malignancies validates the UPS as a viable therapeutic pathway, and substantial effort is now focused on the development of both second-generation proteasome inhibitors as well as novel strategies for the inhibition of upstream UPS enzymes. In this review we discuss the potential 'druggability' of key nodes within the UPS and summarize recent advances within the field.
Insights
The ubiquitin-dependent proteolysis system (UPS) is crucial for protein degradation and linked to human diseases. Targeting UPS enzymes, like proteasomes, offers promising therapeutic strategies for various conditions.
Area of Science:
- Biochemistry
- Molecular Biology
- Cell Biology
Background:
- The ubiquitin-dependent proteolysis system (UPS) regulates protein degradation in eukaryotic cells.
- Dysfunctions in the UPS are implicated in numerous human pathologies.
- Proteasome inhibitors have shown success in treating hematological malignancies.
Purpose of the Study:
- To review the therapeutic potential of targeting key nodes within the UPS.
- To summarize recent advancements in UPS-targeted drug development.
- To discuss the 'druggability' of UPS enzymes.
Main Methods:
- Literature review of recent scientific publications.
- Analysis of therapeutic strategies targeting UPS enzymes.
- Discussion of proteasome inhibitors and upstream UPS enzyme inhibition.
Main Results:
- The UPS is a validated therapeutic target, particularly for cancer.
- Development of second-generation proteasome inhibitors is ongoing.
- Novel strategies for inhibiting upstream UPS enzymes are emerging.
Conclusions:
- Targeting the UPS represents a promising therapeutic avenue.
- Further research into UPS enzyme inhibition could yield new treatments.
- The UPS offers significant potential for drug development in human diseases.
Related Concept Videos
The Proteasome
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3 (ubiquitin...
The Proteasome
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
The Proteasome
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
The Proteasome Structure
The proteasome is an...
Regulated Protein Degradation
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
Regulated Protein Degradation
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...

